VYGR

VYGR is a pre-revenue-in-substance, clinical-stage CNS biotech: the $40.4M of FY2025 'revenue' is lumpy collaboration/milestone income (note the $250M FY2023 spike that flipped to a $132M profit, then reverted), not product sales, so the -49.5% YoY drop and -296.5% net margin are noise around a pipeline story rather than a deteriorating operating business. What actually matters is the balance sheet against the burn. Voyager runs a ~$132M annual operating cash outflow with only $65.3M of cash & equivalents, though current assets of $203M vs. just $26.5M current liabilities imply another ~$130M in short-term investments — call it roughly 1.5 years of runway. Liabilities/equity of 0.29x and a ~7.7x current ratio make this one of the healthier clinical-biotech balance sheets, but the +8% YoY share count and the funding gap make an equity raise a question of when, not if.

The filing tightens the thesis in Voyager's favor on optionality. The wholly-owned pipeline is now focused on two tau programs for Alzheimer's: VY7523 (anti-tau antibody) is in a Phase 1 MAD trial with initial tau-PET imaging data expected 2H 2026, and VY1706 (tau-silencing gene therapy off the TRACER capsid platform) had a Type C FDA meeting in Q1 2026, with an IND targeted for Q2 2026 and a trial start in 2H 2026. Crucially, Voyager is not going it alone: partnered programs with Neurocrine (FA/GBA1, with retained 40%/50% U.S. opt-ins), Alexion/AstraZeneca and Novartis provide external validation of the TRACER platform and non-dilutive capital, and Neurocrine intends to start an FA trial (NBIB-223) in 2H 2026. That partner roster is the single best reason this is a hold rather than an avoid.